David Michelson, M.D., received his BA in English from Wesleyan University. Following a period of service as a teacher in the Peace Corps, he received his MD from the Albert Einstein College of Medicine in New York. He completed his internship and residency in Psychiatry at Yale University, where he was also a chief resident and faculty member prior to moving to the National Institute of Mental Health as a member of the clinical neuroendocrinology branch. During his tenure at the National Institute of Mental Health, Dr. Michelson's research focused on the HPA axis, including development of investigative methodologies for assessing HPA axis regulation, and elucidating the pathophysiology and clinical sequelae of HPA axis activation in depression, as well as understanding the somatic consequences of depression-associated hypercortisolism. Dr. Michelson joined Eli Lilly and Company as a clinical research physician in 1996. In 1999 he became the medical director and later senior medical director for the atomoxetine development group (Strattera, a compound for ADHD), and led its clinical development and regulatory submissions in the US and globally. In 2003 he became the executive medical director of the Neuroscience Therapeutic Area, with responsibility for overseeing Lilly's early phase neuroscience clinical development program, including compounds with psychiatric, neurologic and pain/migraine indications. He also was a member of Eli Lilly’s corporate governance team managing the company's early phase portfolio. In 2006, Dr. Michelson joined Merck in his current position as the vice president for neuroscience and ophthalmology clinical research.